Barclays
IMCR icon

Barclays’s Immunocore IMCR Stock Holding History

Barclays’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,000
Closed -$1.63M – 5072
2024
Q1 		$1.63M Buy
+25,000
New +$1.72M ﹤0.01% 2744

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Barclays's IMCR Position: Q2 2026 in Review

Barclays reduced its Immunocore (IMCR) stake by 4.5% in Q2 2026, selling an estimated $41.2K and leaving 29,517 shares worth $937K. The position accounts for ﹤0.01% of the portfolio, ranked #2828.

Barclays first reported a position in IMCR in Q1 2022 and has held it in 18 quarters since. The position peaked at $11.8M in Q2 2023. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Barclays held 29,517 shares of Immunocore worth $937K as of Q2 2026.
  • Barclays sold 1,392 Immunocore shares in Q2 2026, an estimated $41.2K.
  • Immunocore made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2828 holding.
  • Barclays first reported a position in Immunocore in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Immunocore position peaked at $11.8M in Q2 2023.
  • 135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.